Designer oestrogens: Fact or fantasy?

Lancet

Volumn 350, Issue 9079, 1997, Pages 676-677

  Compston, J E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE;

BONE; BREAST CANCER; CANCER RISK; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; SHORT SURVEY; THROMBOEMBOLISM;

EID: 0030767496     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)22036-2     Document Type: Note

References (11)

1. F Grodstein MJ Stampfer JE Manson Postmenopausal estrogen and progestin use and the risk of cardiovascular disease N Engl J Med 335 1996 453 461
2. C Kawas S Resnick A Morrison A prospective study of estrogen replacement therapy and the risk of developing Alzhemier's disease: the Baltimore longitudinal study of aging Neurology 48 1997 1517 1521
3. GA Colditz SE Hankinson DJ Hunter The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med 332 1995 1589 1593
4. E Daly MP Vessey MM Hawkins JL Carson P Gough S Marsh Risk of venous thromboembolism in users of hormone replacement therapy Lancet 348 1996 977 980
5. SAA Beresford NS Weiss LF Voight B McKnight Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women Lancet 349 1997 458 461
6. JE Compston Prevention and management of osteoporosis: current trends and future prospects Drugs 53 1997 727 735
7. F Grodstein MJ Stampfer GA Colditz Postmenopausal hormone therapy and mortality N Engl J Med 336 1997 1769 1775
8. DP McDonnell DL Clemm T Hermann ME Goldman JW Pike Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens Mol Endocrinol 9 1995 659 669
9. NN Yang M Venugopalan S Hardikar A Glasebrook Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene Science 273 1996 1222 1225
10. MW Draper DE Flowers WJ Huster JA Neild KD Harper C Arnaud A controlled trial of raloxifene (LY139481) HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women J Bone Miner Res 11 1996 835 842
11. Delmas PD, Bjarnason NH, Mitlak B, et al. Raloxifene HCl prevents bone loss and lowers serum cholesterol without endometrial stimulation in early postmenopausal women. Proc Endocr Soc (in press)